nitrendipine has been researched along with Liver Diseases in 5 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The half-life, AUC, and bioavailability also seem to be altered only in a more severe state of liver disease." | 5.27 | Disposition of nitrendipine in patients with chronic liver diseases. ( Gothe, M; Rämsch, KD; Zilly, W, 1988) |
| " The terminal half-life is on average 8 h, and thus substantially longer than the terminal half-life of 2-3 h for nifedipine." | 2.37 | Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ( Eichelbaum, M; Fischer, C; Kuhlmann, U; Machleidt, C; Mast, V; Mikus, G, 1988) |
| " The time to Cmax was not significantly different in the two groups." | 1.27 | Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ( Burkholder, DE; Krol, GJ; Lasseter, KC; Murdoch, AA; Shamblen, EC; Taylor, RJ; Vanov, SK, 1984) |
| " The half-life, AUC, and bioavailability also seem to be altered only in a more severe state of liver disease." | 1.27 | Disposition of nitrendipine in patients with chronic liver diseases. ( Gothe, M; Rämsch, KD; Zilly, W, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lasseter, KC | 1 |
| Shamblen, EC | 1 |
| Murdoch, AA | 1 |
| Burkholder, DE | 1 |
| Krol, GJ | 1 |
| Taylor, RJ | 1 |
| Vanov, SK | 1 |
| Thurman, RG | 1 |
| Apel, ED | 1 |
| Lemasters, JJ | 1 |
| Zilly, W | 1 |
| Rämsch, KD | 1 |
| Gothe, M | 1 |
| Eichelbaum, M | 1 |
| Mikus, G | 1 |
| Mast, V | 1 |
| Fischer, C | 1 |
| Kuhlmann, U | 1 |
| Machleidt, C | 1 |
| Regårdh, CG | 1 |
| Edgar, B | 1 |
| Olsson, R | 1 |
| Kendall, M | 1 |
| Collste, P | 1 |
| Shansky, C | 1 |
1 review available for nitrendipine and Liver Diseases
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease.
Topics: Humans; Kidney Diseases; Liver Diseases; Nitrendipine | 1988 |
4 other studies available for nitrendipine and Liver Diseases
| Article | Year |
|---|---|
Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Chronic Disea | 1984 |
Protective effect of nitrendipine against hypoxic injury in perfused livers from ethanol-treated rats.
Topics: Animals; Ethanol; Female; Fluorescence; Hypoxia; In Vitro Techniques; L-Lactate Dehydrogenase; Liver | 1988 |
Disposition of nitrendipine in patients with chronic liver diseases.
Topics: Adult; Biological Availability; Chromatography, Gas; Chronic Disease; Female; Half-Life; Humans; Liv | 1988 |
Pharmacokinetics of felodipine in patients with liver disease.
Topics: Adult; Aged; Aging; Blood Pressure; Calcium Channel Blockers; Felodipine; Female; Heart Rate; Humans | 1989 |